Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca to Discontinue Bydureon, Zestril amid Weak Sales
February 18, 2022
- Chugai Claims 1st-Ever Title in Japan Pharma Market in 2021 on Brisk Oncologic Performance: IQVIA
February 18, 2022
- Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling
February 17, 2022
- GSK Launches Benlysta Observational Study in SLE Patients with History of Lupus Nephritis
February 17, 2022
- Healios Plans Preapplication Consultation with PMDA on MultiStem as Early as March
February 17, 2022
- GMP Issues Likely to Trigger Ozempic Supply Restrictions in Japan: Novo
February 16, 2022
- Padcev Shows 36.4% Pathologic Complete Response in Bladder Cancer
February 16, 2022
- Opdivo Approved for 5 New Indications in South Korea
February 16, 2022
- Bayer Employee Loses in Damage Suit over Xarelto Scandal
February 15, 2022
- Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- Taiho Files TS-1 for Adjuvant Chemo in Breast Cancer in Japan
February 15, 2022
- Meiji Ditches Ziprasidone Schizophrenia Program in Japan
February 15, 2022
- Chugai to Integrate 2 Chinese Subsidiaries in April
February 15, 2022
- Otsuka’s 4 Global Brands Fare Well to Hit 2023 Target 2 Years Earlier
February 14, 2022
- Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
- Sanofi Files NDA for Rare Blood Disease Drug in Japan
February 14, 2022
- Shionogi, Chiba Univ. Tie Up for Nasal Vaccine Research, Eye COVID-19 Trial in FY2022
February 14, 2022
- Eisai Formally Opposes CMS Coverage Proposal for Aduhelm
February 14, 2022
- Astellas Set to Forge High-Quality Sales Scheme with Global Know-How, Double Online Reps
February 10, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…